Therapeutic effectiveness of neuraminidase-treated allogeneic myeloblasts as immunogen in acute myelocytic leukemia.
Our chemoimmunotherapy study shows significantly longer remission and survival in acute myelocytic leukemia (AML) patients who have been immunized with neuraminidase-treated allogeneic myeloblasts as compared to patients who received chemotherapy alone or neuraminidase-treated myeloblasts plus MER. MER impairs the immunotherapeutic effectiveness of neuraminidase-treated allogeneic myeloblasts in AML patients. The in vivo and in vitro immunologic status in each arm of the protocol correlate well with the duration of remission and survival of the patient.
D001402:B-Lymphocytes / Q000276:immunology; D001500:BCG Vaccine / Q000276:immunology; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D017708:Leukocyte Transfusion; D007962:Leukocytes / Q000032:analysis / Q000276:immunology*; D009169:Mycobacterium tuberculosis / Q000276:immunology; D009439:Neuraminidase / Q000627:therapeutic use*; D012794:Sialic Acids / Q000032:analysis; D013601:T-Lymphocytes / Q000276:immunology
D001500:BCG Vaccine; D012794:Sialic Acids; C011499:methanol extraction residue (MER) tubercle bacillus fraction; D009439:Neuraminidase